National Observational Study On The Use Of Inflectra An Infliximab Biosimilar In Real Life

  • days left to enroll
  • participants needed
  • sponsor
Updated on 26 January 2021
ulcerative colitis
crohn's disease
rheumatoid arthritis
psoriatic arthritis
ankylosing spondylitis
polyarticular arthritis


National, prospective, multicentre observational study designed for eligible patients treated with Inflectra.

Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the response to treatment.

Condition Ankylosing spondylitis, Psoriasis, PSORIATIC ARTHRITIS, Rheumatoid Arthritis, Ulcerative Colitis, Arthritis, Arthritis and Arthritic Pain, Psoriasis and Psoriatic Disorders, Rheumatoid Arthritis (Pediatric), Crohn Desease, Arthritis and Arthritic Pain (Pediatric), Ulcerative Colitis (Pediatric)
Treatment QOL questionaire
Clinical Study IdentifierNCT02925338
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Adult patients treated with Inflectra regardless of treatment phase in one of the following indications consistent with the SPC: Crohn's Disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
Paediatric patients (children and adolescents between 6 and 17 years old) treated with Inflectra, regardless of treatment phase from the time when Inflectra is prescribed in accordance with the indications listed in the SPC Crohn's Disease or ulcerative colitis Patients (or their legal representatives) who have received information (verbally and in writing) about the study and agreed to take part in it
Patients who have given their agreement for their clinical data and their medical file to be accessed by signing the information leaflet

Exclusion Criteria

Patients who refuse access to their medical file for collection of: their medical data
Patients not treated with Inflectra
Patients treated with Inflectra for psoriasis
Patients with a past history of hypersensitivity to infliximab, to other murine proteins or to one of the excipients in Inflectra
Patients with tuberculosis or any other severe infection such as sepsis, abscess or opportunistic infection
Patients with moderate to severe heart failure (NYHA III/IV)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note